Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTT-OV001
- Development stage
- Phase 1
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
PTT-OV001 is an investigational oncolytic virus therapy being developed by the Langfang Campus of Cancer Hospital, Chinese Academy of Medical Sciences, for the treatment of advanced, unresectable, or metastatic solid tumors. As an oncolytic virus, it is designed to selectively infect, replicate within, and lyse malignant cells, thereby releasing tumor-associated antigens and promoting an immunogenic environment. It is administered via local injection (intratumoral) and is currently undergoing Phase 1 clinical evaluation in China as both a monotherapy and in combination with PD-1 checkpoint inhibitors for patients who have exhausted standard therapeutic options.
Beyond the preview
Go deeper on PTT-OV001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTT-OV001.